Clinical Trial Update: Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers [Phase 3]

View source ↗

Summary

Phase 3 trial comparing the live attenuated Japanese encephalitis vaccine IMOJEV with CD.JEVAX in toddlers, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• CD.JEVAX (Japanese encephalitis vaccine)
• IMOJEV

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Japanese Encephalitis, Japanese Encephalitis Virus Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-04-25